Additional file 2 of Association of baseline neutrophil-to-eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma

Additional file 2: Supplemental Figure 1: PFS and OS by median NER and NLR among intermediate/poor risk. A) Median PFS was 8.2 mo in the mNER group (n=46) (HR 0.55, p=0.01). B) Median OS was NR in the mNER group (n=46) (HR 0.32, p